X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR)

Historical Holders from Q1 2019 to Q3 2025

Symbol: XFOR on Nasdaq
Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 7,938,059
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 2,507,092
Holdings value: $8,574,256
% of all portfolios: 0%
Number of holders: 2
Number of buys: 2
Average buys %: +0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	4.8%		$1,558,172		8,200,903		The Vanguard Group	31 Dec 2024
ORBIMED ADVISORS LLC	1.7%		$25,640		134,947		ORBIMED ADVISORS LLC	30 Jun 2025

Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	2,507,092	$8,574,256	+$6,340,007			$3.42	2
2025 Q2	653,289	$1,241,249	-$59,123,616	$0	$0	$1.90	2
2025 Q1	98,484,813	$23,301,713	-$1,452,474	$4,823	$118,857	$0.2364	91
2024 Q4	99,822,228	$73,237,480	-$4,976,749	$61,199	$309,967	$0.7336	89
2024 Q3	100,589,647	$67,319,848	-$551,327	$33,886	$142,924	$0.6693	98
2024 Q2	101,516,641	$58,880,322	-$4,474,635	$41,586	$126,382	$0.5800	97
2024 Q1	102,998,180	$143,153,751	+$10,326,109	$403,795	$286,479	$1.39	96
2023 Q4	96,800,089	$81,168,367	-$18,734,277	$122,370	$58,822	$0.8385	92
2023 Q3	112,423,967	$122,551,525	-$3,809,593	$178,651	$105,948	$1.09	91
2023 Q2	112,930,152	$219,074,939	+$103,525,068	$736,424	$10,374,614	$1.94	96
2023 Q1	60,979,055	$53,052,409	+$698,212	$124,845	$43,326	$0.8700	56
2022 Q4	60,622,175	$60,205,215	+$20,545,513	$191,308	$141,212	$0.9930	52
2022 Q3	39,133,898	$66,911,740	+$39,611,313	$176,000	$44,000	$1.71	54
2022 Q2	16,046,519	$15,520,101	-$680,561	$31,000	$24,000	$0.9650	44
2022 Q1	16,343,188	$28,602,538	-$2,230,268	$220,000	$37,000	$1.75	52
2021 Q4	17,568,471	$40,229,950	-$2,286,455	$389,000	$181,000	$2.29	49
2021 Q3	16,206,198	$85,726,624	-$2,862,733	$60,000	$393,000	$5.29	48
2021 Q2	16,587,201	$107,773,003	+$971,565		$151,000	$6.50	58
2021 Q1	16,126,888	$138,720,293	+$48,924,159			$8.61	59
2020 Q4	10,477,783	$67,370,946	+$1,560,507			$6.43	53
2020 Q3	10,231,522	$69,268,392	-$5,283,243		$0	$6.77	50
2020 Q2	10,703,549	$99,748,639	-$2,349,709		$1,398,000	$9.32	54
2020 Q1	11,262,165	$112,618,520	+$1,382,834		$1,500,000	$10.00	49
2019 Q4	11,047,629	$118,207,922	+$34,786,028		$1,605,000	$10.70	53
2019 Q3	7,738,772	$98,353,473	+$1,731,349		$636,000	$12.71	49
2019 Q2	7,594,683	$113,920,545	+$87,071,950		$750,000	$15.00	43
2019 Q1	1,788,795	$31,139,000	+$31,139,000			$17.41	29